PartnershipJul 21, 2026, 07:31 AM
PolyPid Partners with Azurity for D-PLEX100; $320M+ Payments
AI Summary
PolyPid Ltd. has entered into an exclusive commercial partnership with Azurity Pharmaceuticals for the commercialization of D-PLEX100 in the United States and Canada. PolyPid stands to receive over $320 million in potential payments, including $30 million upfront and near-term milestones, plus tiered royalties. Azurity will commercialize the product and fund its clinical development for potential label expansion, while PolyPid will manufacture and supply D-PLEX100 and retain global rights outside the partnered territories. This collaboration follows positive Phase 3 results for D-PLEX100 and its recent NDA submission to the FDA.
Key Highlights
- PolyPid to potentially receive over $320 million in upfront and milestone payments.
- Includes $30 million in upfront and near-term milestone payments ($15M upon signing, $15M upon FDA NDA acceptance).
- PolyPid is eligible for up to approximately $300 million in additional regulatory, development, and sales-based milestone payments.
- PolyPid will receive tiered royalties ranging from mid-teen to mid-twenties percentages.
- Azurity Pharmaceuticals will commercialize D-PLEX100 in the U.S. and Canada and fund clinical development for label expansion.
- PolyPid will manufacture and supply D-PLEX100 and retains global commercial rights outside the U.S. and Canada.
- The partnership follows positive Phase 3 SHIELD II results and PolyPid's recent NDA submission to the FDA.
Price Impact
More from PYPD